Literature DB >> 6332673

The use of cytotoxic T cells in the regulation of tumour growth in syngeneic mice.

L Kwong, D G Kilburn, H S Teh.   

Abstract

Normal C57BL/6 (B6) spleen cells were cultured with syngeneic EL4 tumour cells, expanded in IL2-containing medium, and tested for anti-tumour activity in vitro and in vivo. The activated cells were highly cytotoxic for EL4 and to a lesser degree killed syngeneic B6 blasts and allogeneic (D2) P815 tumour cells. B6 or BDF1 mice that received these cultured cells by IP injection cleared 125IUdR-labelled EL4 cells faster than untreated mice. However, this enhanced clearance was evident only 7-12 days after injection. Since the injected cells had a short half-life (less than 10% remaining after 48 h) the effect of these cells in vivo was most probably due to the activation of the host's immune system. Mice that received cultured cells survived significantly longer than untreated mice following a lethal dose of EL4 cells. Cultured cells were much more effective in prolonging survival when used in conjunction with cyclophosphamide (CY). In animals receiving either cultured cells with or without CY or CY alone tumour clearance was markedly enhanced 7-12 days after injection. When challenged with a small dose of EL4 tumour cells (1 X 10(4) SC per mouse) three of ten B6 mice treated with B6 anti-EL4 cultured cells were able to survive indefinitely. The frequency of CTL precursors to EL4 from the spleen cells of these surviving animals was about five-fold higher than that of normal spleen cells. Furthermore, CTL derived from primed spleen cells were more specific for EL4 than those derived from normal spleen cells.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6332673     DOI: 10.1007/bf00205487

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  33 in total

1.  Long term culture of tumour-specific cytotoxic T cells.

Authors:  S Gillis; K A Smith
Journal:  Nature       Date:  1977-07-14       Impact factor: 49.962

Review 2.  Passive immunotherapy of cancer in animals and man.

Authors:  S A Rosenberg; W D Terry
Journal:  Adv Cancer Res       Date:  1977       Impact factor: 6.242

3.  Inhibition of established transplants of chemically induced sarcomas in syngeneic mice by lymphocytes from immunized donors.

Authors:  H Borberg; H F Oettgen; K Choudry; E J Beattie
Journal:  Int J Cancer       Date:  1972-11       Impact factor: 7.396

4.  Duration of drug levels in mice as indicated by residual antileukemic efficacy.

Authors:  I Kline; M Gang; D D Tyrer; N Mantel; J M Venditti; A Goldin
Journal:  Chemotherapia (Basel)       Date:  1968

5.  A simple method for the quantitation of specific cytotoxic precursors to syngeneic tumors.

Authors:  H S Teh; L Kwong; M Yu; D G Kilburn
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

6.  Immunity to lymphoid tumors in syngeneic mice by immunization with mitomycin C-treated cells.

Authors:  E Benjamini; S Fong; C Erickson; C Y Leung; D Rennick; R J Scibienski
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

Review 7.  The in vivo effects of interleukin 2 (TCGF).

Authors:  H Wagner; C Hardt; K Heeg; K Pfizenmaier; H Stötter; M Röllinghoff
Journal:  Immunobiology       Date:  1982-03       Impact factor: 3.144

8.  Generation of cytotoxic lymphocytes to syngeneic tumors by using co-stimulator (Interleukin 2): in vivo activity.

Authors:  G B Mills; G Carlson; V Paetkau
Journal:  J Immunol       Date:  1980-11       Impact factor: 5.422

9.  Quantitative studies on the precursors of cytotoxic lymphocytes. II. Specificity of precursors responsive to alloantigens and to concanavalin A.

Authors:  H S Teh; R A Phillips; R G Miller
Journal:  J Immunol       Date:  1977-03       Impact factor: 5.422

10.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

View more
  1 in total

1.  Modulation of the immune response to tumors by a novel synthetic compound, (4R)-3-benzoyl-N-[(1R)-1-phenylethyl]-4-thiazolidinecarboxamide (RS-0481).

Authors:  S Kurakata; M Tomatsu; M Arai; H Arai; A Hishinuma; H Kohno; K Kitamura; T Kobayashi; K Nomoto
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.